FDA Pauses Emergency Use Authorization for Last Remaining COVID-19 Monoclonal Antibody Treatment

What**'**s the**news. ** The U.S. Food and Drug Administration (FDA) has announced that the medication bebtelovimab is no longer authorized for emergency use as it is no longer expected to neutralize certain Omicron subvariants of the SARS-CoV-2 virus, the agency says in a November 30, 2022, statement.